文献速递慢病防控与筛查免疫规划卫生政策与健康促进

BCG成功故事:从预防结核病到优化膀胱癌治疗

A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment.
PubMed 文献 · Vaccine · 2021-08-18

本综述回顾了BCG膀胱内灌注免疫治疗获批并全球接受的历程,并指出现代免疫治疗昂贵而BCG低成本导致供应短缺。文中汇总了1976年首次报告的6次每周5x10^8 CFU膀胱内灌注方案优于单纯切除和切除加膀胱内化疗,以及3周维持方案在随机临床试验中降低疾病进展和死亡率。

要点

  • 膀胱肿瘤切除后每周膀胱内灌注5x10^8 CFU BCG共6次优于单纯切除及切除加化疗。
  • 诱导后3、6、12、18、24、30和36个月各3周BCG维持可进一步显著减少肿瘤复发。
  • 3周BCG维持方案在多中心随机临床试验中降低疾病进展和死亡率。

核心结论

  • BCG仍是结核病最重要的疫苗,且已成为治疗侵袭性局限性膀胱癌最广泛接受的有效药物。
  • BCG低成本导致低利润,反复短缺威胁膀胱癌患者和结核病风险儿童。
  • 重组技术有望提高BCG疗效和生产,扩大供应并缓解短缺。

研究设计与样本

  • 综述,回顾BCG膀胱癌免疫治疗获批和全球接受的历程。

主要发现

  • 1976年首次报告膀胱肿瘤切除后每周6次膀胱内灌注5x10^8 CFU BCG,优于单纯切除和切除加膀胱内化疗。
  • 诱导后3、6、12、18、24、30和36个月各3周BCG维持可进一步显著减少肿瘤复发。
  • 3周BCG维持方案在多中心随机临床试验中降低疾病进展和死亡率。

关键数值与推荐

  • 膀胱内灌注方案:每周5x10^8 CFU BCG,共6次,于膀胱肿瘤切除后。
  • 维持方案:诱导后3、6、12、18、24、30和36个月各3周治疗。

临床怎么用

  • 膀胱肿瘤切除后可采用每周6次5x10^8 CFU BCG膀胱内灌注。
  • 诱导后按3、6、12、18、24、30和36个月各3周进行BCG维持。
  • 需关注BCG供应短缺对膀胱癌治疗和结核病预防的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BCG remains the most important vaccine for tuberculosis 100 years after its first use, and over the past 4 decades it has become the most widely accepted, effective drug used in the treatment of aggressive localized bladder cancer. This review chronicles the narrow path that led to approval and world-wide acceptance of BCG immunotherapy for bladder cancer while immunotherapy trials in other malignancies were abandoned. Six intravesical instillations of 5x10^8 CFU of BCG weekly after bladder tumor resection, first reported in 1976, is superior to resection alone and resection plus intravesical chemotherapy. Maintenance of effective immune stimulation is surprisingly difficult, but 3 weekly treatments 3, 6, and 12, 18, 24, 30 and 36 months after induction produces further significant reduction in tumor recurrence. This 3 week BCG maintenance schedule alone has reduced disease progression and mortality in multicenter randomized clinical trials. In the new age of immuno-oncology patients with many types of cancer now benefit from immunotherapy, but currently these modern agents are prohibitively expensive for most of the world. In contrast, the low cost and therefore low profitability of BCG has resulted in recurrent shortages that threaten both bladder cancer patients and children at risk for tuberculosis and other serious infections. Humanity has greatly benefited from early 20th century science that developed BCG and the benevolence of doctors Calmette and Guerin who put people over profit and widely shared cultures of the vaccine. The 21st century is bringing new immunotherapies and greatly expanding the types of malignancies that can be treated. Recombinant technology is expected to improve both the efficacy and production of BCG, hopefully expanding the availability of BCG and relieving the recurring supply shortage for both vaccination and cancer therapy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lamm DL, Morales A. A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment. Vaccine. 2021. PMID: 34417051. doi:10.1016/j.vaccine.2021.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。